Media ReleasesStirling Products Limited

View All Stirling Products Limited News


Milestone HDA Licensing Agreement and Progress

Healthcare group, Stirling Products Limited (ASX:STI) is pleased to advise:

High Density Aerosol (HDA) License Agreement

The Company and its joint venture partner, Zodiac Capital Limited have entered into a conditional Agreement with a St Petersburg based Cice Group company for the exclusive use of the joint venture's licensed High Density Aerosol (HDA) for the pulmonary delivery of a proprietary form of deltaran. Deltaran has been approved in Russia to treat brain damage, dementia and Alzheimer's disease.


For further information please download PDF below:

Download this document